Клиническая и экспериментальная тиреоидология (Jun 2015)
Polymorphism of Gly482Ser PPARGC 1A and Ala203Pro PPARGC 1B in the pathogenesis of Graves’ orbitopathy
Abstract
Aim. To examine the association of polymorphisms Gly482Ser PPARGC 1A and Ala203Pro PPARGC 1B with the development of thyroid eye disease (TEO). Materials and methods. A total of 88 people: 52 patients with TEO, 36 - healthy individuals. Identified polymorphisms Gly482Ser PPARGC 1A and Ala203Pro PPARGC 1B by PCR. Results. When TEO detected differences in the frequency of allele and genotype SNPs investigated compared with the control. The prevalence of genotypes and alleles in patients with TEO (Gly/Gly - 38.5%, Gly/Ser - 34.6%, Ser/Ser - 26.9%, Gly-allele - 55.8%, Ser-allele - 44.2% gene PPARGC 1A; Ala/Ala - 19.2%, Ala/Pro - 55.8%, Pro/Pro - 25%, Ala-allele - 47.1%, Pro-allele - 52.9% gene PPARGC 1B). The prevalence of genotypes and alleles in the control group (Gly/Gly - 38.9%, Gly/Ser - 44.4%, Ser/Ser - 16.7%, Gly-allele - 61.1%, Ser-allele - 38.9% of the gene PPARGC 1A; Ala/Ala - 25%, Ala/Pro - 58.3%, Pro/Pro - 16.7%, Ala-allele - 54.2%, Pro-allele - 45.8% of the gene PPARGC 1B). Conclusion. At TEO more common genotypes Ser482Ser PPARGC 1A, Pro203Pro PPARGC 1B and Ser allele polymorphism Gly482Ser PPARGC 1A, Pro polymorphism Ala203Pro PPARGC 1B, as well as less common genotypes Gly482Ser PPARGC 1A, Ala203Ala PPARGC 1B and Gly allele polymorphism Gly482Ser PPARGC 1A, Ala polymorphism Ala203Pro PPARGC 1B. Polymorphisms and allele Gly482Ser PPARGC 1A gene and gene Ala203Pro PPARGC 1B do not modify the risk of TEO.
Keywords